Cancer Immunotherapy: An Overview
- Review of the current therapeutic landscape and best practices for immune checkpoint inhibitors in oncology
- Professional resources for oncology clinicians during COVID-19
Case-Based Applications and Guidance for Multidisciplinary irAE Management
- Differentiating irAE-related toxicities from other etiologies including viral infection and strategies for optimal management
- Educating patients to recognize and report irAEs and counseling on expectations of cancer care during COVID-19
Clinical Pearls for the Care of Patients on Cancer Immunotherapy
Question and Answer Session
Date / Time
John Thompson, MD
Professor of Medicine
Division of Medical Oncology
University of Washington
Stephanie Andrews, MS, ANP-BC
College of Nursing
University of South Florida
Internal Hospital Medicine
H. Lee Moffitt Cancer Center and Research Institute
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP
Adult Specialty Program
Yale University School of Nursing
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with cancer who are eligible for treatment with immune checkpoint inhibitors.
This program is intended for oncology nurses and other healthcare providers who care for patients with cancer using immunotherapies.
Upon completion of this activity, participants should be able to:
- Describe the different immune checkpoint inhibitors and their current indications for the treatment of patients with cancer
- Understand the unique spectrum of adverse events associated with different immune checkpoint inhibitors based on their mechanism of action
- Communicate with and educate patients to actively monitor and report symptoms that are associated with cancer immunotherapy and an activated immune system
- Assess if and when it is appropriate to withhold, discontinue, and/or resume immune checkpoint inhibitor therapy in the setting of an immune-related adverse event
- Collaborate effectively with colleagues from oncology and nononcology specialties who may be involved with optimal diagnosis and management of immune-related adverse events
- Plan approaches and care pathways for detecting and managing irAEs across tumor types
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-048-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.